Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Budesonide Prophylaxis for Engraftment Syndrome After Hematopoietic Cell Transplantation

NCT05509933 is registered in ClinicalTrials.gov with Henry Ford Health System as lead sponsor.

NCT NCT05509933
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05509933 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Budesonide Prophylaxis for Engraftment Syndrome After Hematopoietic Cell Transplantation
Lead sponsor
Henry Ford Health System
Phase
Phase 3
Overall status
Recruiting
Start date
November 9, 2022
Completion date
December 30, 2027
Enrollment
110 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

engraftment syndrome